Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2011 ) > List of Articles

MINI REVIEW

Hepatitis B: From Blumberg to Bangladesh

Salimur Rahman

Citation Information : Rahman S. Hepatitis B: From Blumberg to Bangladesh. Euroasian J Hepatogastroenterol 2011; 1 (2):42-43.

DOI: 10.5005/jp-journals-10018-1010

License: CC BY-NC 4.0

Published Online: 00-00-0000


Abstract

Bangladesh has made significant progress in all aspects, if hepatitis B management in the recent years. On one hand, we have local generics of most approved antivirals against hepatitis B, including pegylated interferon, which has brought down treatment cost significantly. On the other extreme, significant progress has also been made in the research arena and good quality papers on hepatitis B from Bangladesh are now being published regularly in impact factor journals. Several clinical trials have already been completed, while others are ongoing, which is testimony to the very promising side of hepatology in Bangladesh as a whole.


PDF Share
  1. Rahman S, Mahtab MA, Foster G, Khan M, Karim MF, Solaiman S, et al. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepat Bil Pancreat Dis Int 2008;7(6):595-600
  2. Clinicians guide to viral hepatitis (1st ed) Arnold 2001
  3. Genotypes of hepatitis B virus among chronically infected patients in a tertiary care hospital in Bangladesh. Indian J Gastroenterol 2006;25:219-21
  4. Prevalence of HBeAg negative HBV infection in Bangladeshi IDHAS. J Gastroenterol Hepatol 2008;23(5):28
  5. Early completion of immune clearance state of HBV infection in Bangladesh: An observation. Hepatolog Int 2010;4(1):15
  6. Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers in Bangladesh. Viral Immunology 2010;23(3):335-38
  7. Hepatitis B vaccine: Beyond commercial adjuvants, prophylactic antigens and traditional route of administrations. The 8th JSH Single Topic Conference, Tokyo, Japan 2009;43
  8. Safety, efficacy and immunogenecity of a therapeutic vaccine containing HBsAg and HBcAg by nasal route in patients with chronic hepatitis B. J Hepatolog 2010;52(1):392
  9. Therapeutic potential of a novel therapeutic vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) administered through mucosal and parental route in patients with chronic hepatitis B. Hepatol 2010; 538-39.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.